Dr Matthew Galsky speaks to ecancer about the updated results from a phase 1A dose-escalation study that evaluates FX-909, a first-in-class oral PPARG inhibitor, in heavily pretreated patients with advanced urothelial carcinoma (UC).

Among 40 efficacy-evaluable patients, tumour regressions were observed in 18 of 26 patients with PPARG-high tumours, including 5 confirmed and 1 unconfirmed partial response.

Reductions in ctDNA variant allele frequency were also seen in most evaluable PPARG-high patients.

The treatment showed manageable safety, with common grade ≥3 adverse events including anaemia, thrombocytopenia, and fatigue.

Dr Galsky says that these findings demonstrate clinical proof-of-concept for targeting PPARG in luminal UC, with further evaluation ongoing in a randomised phase 1B expansion study.